Anzeige
Mehr »
Samstag, 08.08.2026 - Börsentäglich über 12.000 News
Schwere Seltene Erden: Entsteht hier die nächste Milliardenstory?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQZ4 | ISIN: US36269B1052 | Ticker-Symbol:
NASDAQ
07.08.26 | 21:59
1,820 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GAIN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GAIN THERAPEUTICS INC 5-Tage-Chart

Aktueller Chart GAIN THERAPEUTICS Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
GAIN THERAPEUTICS INC-Investoren interessieren sich auch für diese Wertpapiere
Innocan Pharma Corporation: Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer TrustMilestone underscores strong consumer confidence, exceptional product quality, and the Company's expanding presence in the U.S. consumer wellness marketHERZLIYA, Israel and CALGARY, Alberta...
► Artikel lesen
Innocan Pharma Corporation: Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness GrowthThe rapidly growing skincare brand continues to strengthen its position in the U.S. beauty market through innovation, quality, and customer trust.HERZLIYA, Israel and CALGARY, AB, July 29...
► Artikel lesen
Innocan Pharma Corporation: Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47MHERZLIYA, Israel and CALGARY, AB, May 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company...
► Artikel lesen
Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter ResultsOrganically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis...
► Artikel lesen
Cronos Group Inc. Announces Results of 2026 Annual Meeting of ShareholdersTORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June...
► Artikel lesen
Cronos Group Inc.: Cronos Group Reports 2026 First Quarter ResultsNet revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter...
► Artikel lesen
Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public OfferingPLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing...
► Artikel lesen
Inovio Pharmaceuticals, Inc.: INOVIO Announces Proposed Public OfferingPLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing...
► Artikel lesen
INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in ChinaResults provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's...
► Artikel lesen